


Autotaxin-IN-3

Cat. No.:	HY-135053		
CAS No.:	2156655-68-2		
Molecular Formula:	C ₂₂ H ₂₁ N ₉ O ₂		
Molecular Weight:	443.46		
Target:	Phosphodiesterase (PDE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (563.75 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions	1 mM	2.2550 mL	11.2750 mL
	5 mM	0.4510 mL	2.2550 mL	
	10 mM	0.2255 mL	1.1275 mL	2.2550 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC ₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1 ^[1] .
IC ₅₀ & Target	Autotaxin 2.4 nM (IC ₅₀)
In Vitro	Autotaxin is an enzyme which is responsible for the increase in lysophosphatidic acid in ascites and plasma, and it is a secretory enzyme important for converting lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA) as a bioactive

signaling molecule^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. Patent O2018212534A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA